AA
IMVT icon

ALPS Advisors’s Immunovant IMVT Stock Holding History

ALPS Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-112,895
Closed -$3.22M – 1019
2024
Q3 		$3.22M Sell
112,895
-1,036
-0.9% -$30.6K 0.02% 284
2024
Q2 		$3.01M Buy
+113,931
New +$3.24M 0.02% 286
2023
Q4 		– Sell
-96,434
Closed -$3.7M – 987
2023
Q3 		$3.7M Buy
96,434
+578
+0.6% +$13.1K 0.03% 239
2023
Q2 		$1.82M Buy
95,856
+10,043
+12% +$187K 0.02% 329
2023
Q1 		$1.33M Sell
85,813
-1,755
-2% -$30.5K 0.01% 385
2022
Q4 		$1.55M Buy
87,568
+23,896
+38% +$301K 0.01% 348
2022
Q3 		$355K Sell
63,672
-5,438
-8% -$26.6K ﹤0.01% 672
2022
Q2 		$270K Sell
69,110
-50,515
-42% -$218K ﹤0.01% 899
2022
Q1 		$659K Sell
119,625
-13,467
-10% -$83.9K 0.01% 381
2021
Q4 		$1.13M Sell
133,092
-7,860
-6% -$64.9K 0.01% 345
2021
Q3 		$1.23M Buy
140,952
+11,904
+9% +$107K 0.01% 367
2021
Q2 		$1.36M Sell
129,048
-48,198
-27% -$673K 0.01% 371
2021
Q1 		$2.84M Buy
177,246
+19,846
+13% +$523K 0.03% 223
2020
Q4 		$7.27M Buy
+157,400
New +$7.28M 0.08% 156

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ALPS Advisors's IMVT Position: Q4 2024 in Review

ALPS Advisors sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 112,895 shares — an estimated $3.22M sold.

ALPS Advisors first reported a position in IMVT in Q4 2020 and held it in 14 quarters. The position peaked at $7.27M in Q4 2020. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • ALPS Advisors reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • ALPS Advisors sold 112,895 Immunovant shares in Q4 2024, an estimated $3.22M.
  • ALPS Advisors first reported a position in Immunovant in Q4 2020 and held it in 14 quarters.
  • ALPS Advisors's Immunovant position peaked at $7.27M in Q4 2020.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on ALPS Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.